| Biomarker ID | 1696 |
| PMID | 26008593 |
| Year | 2015 |
| Biomarker | TTTY15-USP9Y |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | Downregulated in Gleason Upgrade Patients |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 18.0662 (95% CI: 8.7420–37.3355) |
| Effect on Pathways | NA |
| Experiment | Positive Vs Negative Biopsy |
| Type of Biomarker | Diagnostic |
| Cohort | 226 patients were selected for the study. Patients with PSA in range 4-10ng/ml were selected for the study.(n=103). 21 had a positive Biopsy (PCa) and 85 had a negative biopsy (No PCa) |
| Senstivity | 81% |
| Specificity | 75.6% |
| AUC | 0.844 (95% CI: 0.760–0.908) |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | RT-qPCR |
| Clinical | No |
| Remarks | TTTY15-USP9Y score was calculated as 2Ct^[(PSA)-Ct (TTTY15-USP9Y)] X1,000. Cutoff: 76.63 |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |